参松养心胶囊改善冠心病患者室性早搏的临床观察

摘要

目的:观察参松养心胶囊对冠心病室性早搏的临床疗效和安全性.方法:对符合纳入标准的病例采用随机双盲双模拟对照,按1∶1比例随机分为治疗组,给予参松养心胶囊(4粒,每日3次),对照组给予心律平片(100mg,每日3次).1年后,进行室性早搏、主要症状、心电图等疗效及毒副作用的评估.结果治疗组室性早搏显效率36.54％,总有效率71.16％,明显优于对照组显效率17.31％,总有效率46.16％ (P ＜0.05).治疗组临床表现显效率42.31％,总有效率88.46％,明显优于对照组显效率15.38％,总有效率65.38％ (P ＜0.05).治疗组心电图显效率12.24％,总有效率65.30％,明显优于对照组显效率3.92％,总有效率37.25％ (P ＜0.05).结论:参松养心胶囊治疗冠心病室性早搏的疗效确切,临床无毒副作用.%0bjective:To observe the therapeutic effect and safety of Shensongyangxin capsule in treating premature ventricular beat(PVB)of coronary heart disease (CHD).Methods one hundred and four patients with PVB of CHD were randomly divided into treatment group treated with Shensongyanxin capsule (4 capsules once,3 times a day) and control group treated with Propafenonc (100mg once,3 times a day),with a treatment course of 1 years for both groups.The main symptoms and signs,ECG,adverse and toxic reactions were observed before and after treatment.Results In treatment group,the effective rate of premature ventricular beat was 34.6％,total effective rate was 69.2％,which was 19.2％ and 48.1％ respectively in control group.The difference of effective rate between two groups was significant(P ＜ 0.01).In treatment group,the effective rate of clinical symptoms and signs was 42.3％,total effective rate was 88.5％,respectively 15.3％ and 65.3％ in control group.There was a significant difference between the two groups (P ＜ 0.01).In treatment group,the effective rate of ECG was 12.2％,total effective rate was 65.3％,which was 3.9％ and 37.2％ respectively in control group (P ＜ 0.01).Conclusion:Shensongyangxin capsule can be used safely and effectively in the treatment of patients with premature ventricular beat of coronary heart disease.The adverse and toxic reactions were not found in both groups.